SCHEMBL2590764

SCHEMBL2590764

Brc1ccc(-c2nc(NCc3ccccc3)c3ccccc3n2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.81
KMT2A Q03164 8/20 0.81
PDE5A O76074 7/20 0.81
GBA1 P04062 2/20 0.81
ATM Q13315 1/20 0.81
PTGS1 P23219 2/20 0.73
TBXAS1 P24557 2/20 0.73
PTGS2 P35354 2/20 0.73
LMNA P02545 5/20 0.69
MAPT P10636 3/20 0.69
APP P05067 1/20 0.65
CYP1A2 P05177 6/20 0.65
CYP3A4 P08684 6/20 0.65
CYP2D6 P10635 6/20 0.65
CYP2C19 P33261 6/20 0.65
TSHR P16473 4/20 0.65
USP2 O75604 3/20 0.65
HPGD P15428 1/20 0.65
ALDH1A1 P00352 5/20 0.64
HSD17B10 Q99714 4/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864013 0.94 PDE5A (0.81) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1083763 0.90 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1084183 0.87 MEN1 (0.89) MEN1KMT2APDE5AGBA1ATM
SCHEMBL3980498 0.86 PDE5A (0.65) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2583256 0.86 PDE5A (0.90) MEN1KMT2APDE5AGBA1ATM
SCHEMBL12176300 0.86 MEN1 (0.81) MEN1KMT2APDE5AGBA1ATM
SCHEMBL3977603 0.86 PDE5A (0.70) MEN1KMT2APDE5AGBA1ATM
SCHEMBL3981851 0.86 PDE5A (0.70) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4863906 0.85 PDE5A (0.75) MEN1KMT2APDE5AGBA1ATM
SCHEMBL7277479 0.84 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103068393-A Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase CLEAVE BIOSCIENCES INC CLEAVE 2013-04-24 CN disclosed
EP-2566480-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE California Institute of Technology (US) 2013-03-13 EP disclosed
US-8263642-B2 Antimicrobial compounds and methods of use thereof VANDERBILT UNIVERSITY (US) 2012-09-11 US disclosed
US-8263642-B2 Antimicrobial compounds and methods of use thereof VANDERBILT UNIVERSITY (US) 2012-09-11 US disclosed
WO-2011140527-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) 2011-11-10 WO disclosed
WO-2011140527-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) 2011-11-10 WO disclosed
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF VANDERBILT UNIVERSITY 2010-01-07 US disclosed
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF VANDERBILT UNIVERSITY 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF HMOX1, HMOX2, NOD2 MEN1 4247/4885KMT2A 4544/4885PDE5A 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.